Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer.

Published

Journal Article

An extensive Phase I evaluation of human lymphoblastoid interferon has been completed which, in addition to describing its clinical and pharmacological effects, emphasized a broad-scale evaluation of the immune response as a function of interferon dosage. Dose-limiting toxicity was generally due to constitutional symptoms which are remarkably similar to those produced by influenza, although transient peripheral and central neurotoxicity (including deterioration in cognitive and behavioral functions) is observed at higher doses. It is difficult to establish "clean" dose-response effects except for fever and bone marrow suppression, neither of which is a major dose limitation. Enhancement of the immune system was limited to natural killer cells which had a complex dose-response relationship, whereby low interferon concentrations were less stimulatory (than were high doses) following a single dose but gave more sustained stimulation over a 5-week course of 3 times per week i.m. administration. The effects on various measures of monocyte function and of nonspecific immunity (hypersensitivity, immunoglobulins, complement) were negative. We suspect that in practice it may be difficult to exploit the narrow dosage window of immunostimulation, but it is important to note that the nontoxic lower doses were more stimulatory than were the very high doses which are being used in numerous clinical trials.

Full Text

Duke Authors

Cited Authors

  • Laszlo, J; Huang, AT; Brenckman, WD; Jeffs, C; Koren, H; Cianciolo, G; Metzgar, R; Cashdollar, W; Cox, E; Buckley, CE; Tso, CY; Lucas, VS

Published Date

  • September 1, 1983

Published In

Volume / Issue

  • 43 / 9

Start / End Page

  • 4458 - 4466

PubMed ID

  • 6603265

Pubmed Central ID

  • 6603265

Electronic International Standard Serial Number (EISSN)

  • 1538-7445

International Standard Serial Number (ISSN)

  • 0008-5472

Language

  • eng